{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-006188","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.662835+00:00","generated_at":"2026-06-16T23:29:14.270465+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Aytu BioPharma explores strategic alternatives and financing to address liquidity; SEC inquiry ongoing","bullets":["Preliminary discussions underway for potential strategic transactions and financing options.","Company cites ongoing liquidity needs; no assurance that any deal will materialize.","Equity financings would provide liquidity but could be dilutive to existing stockholders.","SEC inquiry active regarding proposed restatements; timing of restatement and Q2 10-Q filing uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-006188","json":"https://secwatch.observer/filing/0001558370-23-006188.json","markdown":"https://secwatch.observer/filing/0001558370-23-006188.md","text":"https://secwatch.observer/filing/0001558370-23-006188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023006188/0001558370-23-006188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023006188/aytu-20230419x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T23:29:14.270465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}